how does glp 1 semaglutide work Work? Mechanism, Benefits & Effects Webster Pharmacy - Semaglutide Compounding

doi: 10.1016/j.cell.2006.02.043 126 LeeS.LeeS

Sands, Ph.D., et al

News provided by Eli Lilly and Company Jun 06, 2026, 14:30 ET In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes common obesity-related conditions

How to Stay Comfortable Supportive supplements can make a difference

Continue learning Where to read next Not medical advice

In recent years, that catalog has grown to include popular weight loss medications like Wegovy and Ozempic